Literature DB >> 10219981

Repeated administration of delta9-tetrahydrocannabinol produces a differential time related responsiveness on proenkephalin, proopiomelanocortin and corticotropin releasing factor gene expression in the hypothalamus and pituitary gland of the rat.

J Corchero1, J Manzanares, J A Fuentes.   

Abstract

The purpose of the present study was to explore the time related effects of repeated administration of delta9-tetrahydrocannabinol on opioid and corticotropin releasing factor gene expression in the hypothalamus and pituitary gland of the rat. By using in situ hybridization histochemistry, the effects of delta9-tetrahydrocannabinol (THC, 5 mg/kg per day; i.p.) were examined after 1, 3, 7 and 14 days of repeated administration on; (1) proenkephalin gene expression in the paraventricular (PVN) and ventromedial nuclei (VMN) of the hypothalamus, (2) proopiomelanocortin gene expression in the arcuate nucleus (ARC) of the hypothalamus and anterior (AL) and intermediate lobe (IL) of the pituitary gland, and (3) corticotropin releasing factor gene expression in the PVN. The results revealed that, in most of the hypothalamic and pituitary regions examined, repeated cannabinoid administration upregulates opioid and corticotropin releasing factor gene expression. However, the onset, the degree of magnitude of gene expression reached and the time related effects produced by repeated administration with delta9-tetrahydrocannabinol are dependent upon the brain and pituitary regions examined. Taken together, the results of the present study suggest that cannabinoids produce a time related differential responsiveness in opioid and corticotropin releasing factor gene expression, in areas of the hypothalamus and pituitary that may be related, at least in part, to a molecular integrative response to behavioral, endocrine and neurochemical alterations that occur in cannabinoid drug abuse.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10219981     DOI: 10.1016/s0028-3908(98)00195-6

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  Cannabinoids Activate Monoaminergic Signaling to Modulate Key C. elegans Behaviors.

Authors:  Mitchell D Oakes; Wen Jing Law; Tobias Clark; Bruce A Bamber; Richard Komuniecki
Journal:  J Neurosci       Date:  2017-02-10       Impact factor: 6.167

2.  Absence of delta -9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice.

Authors:  A Zimmer; E Valjent; M Konig; A M Zimmer; P Robledo; H Hahn; O Valverde; R Maldonado
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

3.  Differential regulation of synaptic inputs by constitutively released endocannabinoids and exogenous cannabinoids.

Authors:  Shane T Hentges; Malcolm J Low; John T Williams
Journal:  J Neurosci       Date:  2005-10-19       Impact factor: 6.167

Review 4.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

5.  Liver portal fibrosis in dioxin receptor-null mice that overexpress the latent transforming growth factor-beta-binding protein-1.

Authors:  Javier Corchero; Gervasio Martín-Partido; Sarah L Dallas; Pedro M Fernández-Salguero
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

Review 6.  Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings.

Authors:  Andrew J Kesner; David M Lovinger
Journal:  J Neurochem       Date:  2021-05-16       Impact factor: 5.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.